Powis G - Search Results

1

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Ihle NT, et al. Among authors: powis g. Cancer Res. 2009 Jan 1;69(1):143-50. doi: 10.1158/0008-5472.CAN-07-6656. Cancer Res. 2009. PMID: 19117997 Free PMC article.

2

PI-3-Kinase inhibitors in colorectal cancer.

Ihle NT, Powis G, Kopetz S. Ihle NT, et al. Among authors: powis g. Curr Cancer Drug Targets. 2011 Feb;11(2):190-8. doi: 10.2174/156800911794328448. Curr Cancer Drug Targets. 2011. PMID: 21158718 Review.

3

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.

Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G. Ihle NT, et al. Among authors: powis g. Mol Cancer Ther. 2004 Jul;3(7):763-72. Mol Cancer Ther. 2004. PMID: 15252137

4

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G. Ihle NT, et al. Among authors: powis g. Mol Cancer Ther. 2005 Sep;4(9):1349-57. doi: 10.1158/1535-7163.MCT-05-0149. Mol Cancer Ther. 2005. PMID: 16170026 Free PMC article.

5

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.

Williams R, Baker AF, Ihle NT, Winkler AR, Kirkpatrick L, Powis G. Williams R, et al. Among authors: powis g. Cancer Chemother Pharmacol. 2006 Oct;58(4):444-50. doi: 10.1007/s00280-006-0190-0. Epub 2006 Feb 17. Cancer Chemother Pharmacol. 2006. PMID: 16485116 Free PMC article.

6

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.

Powis G, Wipf P, Lynch SM, Birmingham A, Kirkpatrick DL. Powis G, et al. Mol Cancer Ther. 2006 Mar;5(3):630-6. doi: 10.1158/1535-7163.MCT-05-0487. Mol Cancer Ther. 2006. PMID: 16546977 Free PMC article.

7

Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway.

Powis G, Ihle N, Kirkpatrick DL. Powis G, et al. Clin Cancer Res. 2006 May 15;12(10):2964-6. doi: 10.1158/1078-0432.CCR-06-0617. Clin Cancer Res. 2006. PMID: 16707590 No abstract available.

8

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha.

Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G. Koh MY, et al. Among authors: powis g. Mol Cancer Ther. 2008 Jan;7(1):90-100. doi: 10.1158/1535-7163.MCT-07-0463. Mol Cancer Ther. 2008. PMID: 18202012

9

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.

Ihle NT, Powis G. Ihle NT, et al. Among authors: powis g. Mol Cancer Ther. 2009 Jan;8(1):1-9. doi: 10.1158/1535-7163.MCT-08-0801. Mol Cancer Ther. 2009. PMID: 19139107 Free PMC article. Review.

10

Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.

Ihle NT, Lemos R, Schwartz D, Oh J, Halter RJ, Wipf P, Kirkpatrick L, Powis G. Ihle NT, et al. Among authors: powis g. Mol Cancer Ther. 2009 Jan;8(1):94-100. doi: 10.1158/1535-7163.MCT-08-0714. Mol Cancer Ther. 2009. PMID: 19139117 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

363 results

Search Page